Ticker brief · 2026-06-22
IDYA IDEAYA BIOSCIENCES INC
IDYA bulls emphasize MTAP progress and valuation upside
Consumer, Non-cyclical · Biotechnology
Lean: bullishlast close
$37.65
1 day
+4.1%
14 days
+20.6%
mkt cap
$3.6B
signals 14d
8
authors 14d
3
The tape is bullish, led by credible biotech accounts emphasizing IDE892 progress, undervaluation, and a supportive oncology BD backdrop. The late-week shift was from clinical-update distribution toward valuation urgency, with multiple credible voices arguing IDYA is materially mispriced. Trade structure reads as a catalyst-plus-valuation setup anchored on IDE892 execution and sell-side upside framing.
BULL CAMP
Bulls argue IDYA has an underappreciated MTAP franchise, with IDE892 moving into combination studies and outside validation from LifeSci’s Outperform view. The higher-conviction late-week voices shifted from pipeline progress to outright valuation upside.
Key voices@bioinvestor24MEDIUM-HIGHA+1.35@semodoughMEDIUM-HIGHC-0.75@Biotech2k1MEDIUM-HIGHA-0.03@BioStocksMEDIUM-HIGHC-0.39
“IDYA is described as deeply undervalued, with a sale threshold framed well above current levels.”— @Biotech2k1 · tweet ↗
BEAR / SKEPTIC
—
Hypotheses6direction · basis · magnitude · supporters — NEW = first seen this week
▲IDE892’s potentially best-in-class profile and broader MTAP toolkit make IDYA’s oncology platform underappreciated by the market.
@semodoughMEDIUM-HIGHC-0.751s
▲IDE892 entering a Phase 1/2 combination study advances the MTAP-deleted cancer program and validates pipeline execution.
▲LifeSci’s Outperform rating and $62 target reinforce a bullish external valuation case for IDYA.
@semodoughMEDIUM-HIGHC-0.751s
▲Fierce oncology business development should support core cancer biotechs and improve IDYA’s strategic scarcity value.
@bioinvestor24MEDIUM-HIGHA+1.351s · insight
▲IDYA is materially undervalued, with bulls implying meaningful upside before they would consider selling.
@bioinvestor24MEDIUM-HIGHA+1.351s · insight@Biotech2k1MEDIUM-HIGHA-0.031s · insight
◆CEO Yujiro Hata becoming chairman signals leadership continuity, but is not a major standalone investment driver.
@theflynewsHIGHC1s
Sellside activity1
LifeSci note PT 62Outperform view tied to IDE892 Phase 1/2 combination progress ahead of guidance.
News / data points4discrete events + data quoted by authors
@BioStocksMEDIUM-HIGHC-0.39
IDEAYA began a Phase 1/2 IDE892 combination study in pancreatic and lung cancers.
@semodoughMEDIUM-HIGHC-0.75
LifeSci assigned an Outperform view with a $62 target and highlighted first-patient-in timing.
@theflynewsHIGHC
IDEAYA elected CEO Yujiro Hata as chairman.
@bioinvestor24MEDIUM-HIGHA+1.35
TNGX’s market cap now sits near twice IDYA’s, underscoring rapid biotech valuation shifts.
Desk readconvergence assessment
The view is highly converged bullish, with no true bear camp in the submitted signals. The strongest support comes from medium-high credibility biotech accounts plus a high-credibility news relay, while lower-credibility participation simply repeats the clinical update. The view would change on weak IDE892 early safety or efficacy signals, or if relative oncology BD interest bypasses IDYA’s MTAP platform.
Tracked hypotheses — caliber-scored view · 2026-06-22
🟡 MEDIUM caliber (1)
📈 h2 bull · score 0.32
IDE892 entering a Phase 1/2 combination study advances the MTAP-deleted cancer program and validates pipeline execution.
- Supporters (3): @BioStocks↗(MEDIUM-,1p), @CrweWorld↗(LOW,1p), @OzmosiHealth↗(MEDIUM,1p)
- Signals: 3 · Max author share: 0.33 · Novelty: stable
- Quote: "IDE892 began a Phase 1/2 combination study in pancreatic and lung cancers." — BioStocks
⚪ LOW caliber (2)
📈 h5 bull · score 0.40
IDYA is materially undervalued, with bulls implying meaningful upside before they would consider selling.
- Supporters (2): @bioinvestor24↗(MEDIUM-,1p), @Biotech2k1↗(MEDIUM-,1p)
- Signals: 2 · Max author share: 0.50 · Novelty: new
- ⚠️ Concentration: 50% from @bioinvestor24↗ MEDIUM-HIGH cred
- Quote: "IDYA is framed as extremely undervalued, with selling unattractive below $50." — Biotech2k1
↔️ h6 neutral · score 0.00
CEO Yujiro Hata becoming chairman signals leadership continuity, but is not a major standalone investment driver.
- Supporters (0):
- Signals: 1 · Max author share: 0.00 · Novelty: stable
- ⚠️ Concentration: 100% from @theflynews↗ HIGH cred
- Quote: "IDEAYA elected CEO Yujiro Hata to the chairman role." — theflynews
🔴 FLAGGED caliber (3)
📈 h3 bull · score 0.10
LifeSci’s Outperform rating and $62 target reinforce a bullish external valuation case for IDYA.
- Supporters (1): @semodough↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @semodough↗ MEDIUM-HIGH cred
- Quote: "LifeSci carried an Outperform view with a $62 target and noted study progress." — semodough
📈 h4 bull · score 0.07
Fierce oncology business development should support core cancer biotechs and improve IDYA’s strategic scarcity value.
- Supporters (1): @bioinvestor24↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: new
- ⚠️ Concentration: 100% from @bioinvestor24↗ MEDIUM-HIGH cred
- Quote: "Oncology BD is expected to be fierce, supporting confidence in core cancer biotechs." — bioinvestor24
📈 h1 bull · score 0.07
IDE892’s potentially best-in-class profile and broader MTAP toolkit make IDYA’s oncology platform underappreciated by the market.
- Supporters (1): @semodough↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @semodough↗ MEDIUM-HIGH cred
- Quote: "Management emphasized IDE892’s best-in-class potential and a broader MTAP toolkit." — semodough
Sentiment — last 14 days
daily mean sentiment, 2026-06-20 → 2026-06-29 · now +0.23 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Biotech2k1 | A | -0.03 | 4 | +0.42 |
| @DeepValueReport | B | +2.52 | 3 | +0.22 |
| @bioinvestor24 | A | +1.35 | 1 | -0.10 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-29 | @Biotech2k1 | +0.25 | Watchlist of value levels across sectors, no explicit buy action. | +3.0% | tweet ↗ |
| 2026-06-29 | @DeepValueReport | +0.20 | Radar/watchlist combining technicals and fundamentals. | +3.0% | tweet ↗ |
| 2026-06-26 | @Biotech2k1 | +0.45 | Lists core portfolio names by category and plans 70% cash before bubble pops, capped to six. | +2.5% | tweet ↗ |
| 2026-06-26 | @DeepValueReport | +0.45 | Lists highest-rated stocks in DVR database with scores. | +2.5% | tweet ↗ |
| 2026-06-25 | @Biotech2k1 | +0.45 | Lists selected top holdings from deep dives, capped to first six tickers. | +3.7% | tweet ↗ |
| 2026-06-24 | @DeepValueReport | +0.00 | Adds three tickers to watchlist without entry intent. | +3.8% | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | -0.10 | Thinks AMGN needs PRMT5 and questions when TNGX would consider a deal. | +7.8% | tweet ↗ |
| 2026-06-20 | @Biotech2k1 | +0.55 | Calls IDYA extremely undervalued and would not sell below $50. | +20.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.